News from Novo - some serious actual science for a change maybe? NN is really pushing the boat out on this one...
This new study retrospectively analysed clinical trial data, which included 1,530 patients with type 2 diabetes, using recursive partitioning analyses to identify factors that predict greatest therapeutic benefit in response to treatment with liraglutide. Responders in the study were defined as those patients achieving a composite endpoint of HbA1c<7% with no weight gain and no hypoglycaemia over 26 weeks.
Key findings from the study include:
Overall 34% of individuals treated with liraglutide 1.8 mg achieved the prespecified composite endpoint in the retrospective analysis.
More patients with HbA1c<8.5% at the start of the study reached the composite endpoint, compared to patients with HbA1c=8.5%, 46% vs19% responders, respectively (p<0.0001).
More patients with HbA1c<8.5% at the start of the study and who had previously received treatment with a single antidiabetic medicine or diet modification
reached the composite endpoint, compared to those who had received combination therapy (56% vs 36% responders, respectively, p<0.0001).
In another subgroup of female patients, more patients with HbA1c<8.5% at the start of the study, previous treatment with a single antidiabetic medicine or diet modification and a shorter duration of diabetes (<4.9 years) reached the composite endpoint, compared to patients with a longer duration of diabetes (=4.9 years), 74% vs 49% responders, respectively (p=0.013).http://en.wikipedia.org/wiki/Liraglutide